Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva - leflunomide - tablet - 20mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - leflunomide - tablet - 10mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - leflunomide - tablet - 20mg

Bandaríkin - enska - NLM (National Library of Medicine)

a-s medication solutions - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide tablets are indicated for the treatment of adults with active rheumatoid arthritis (ra). leflunomide tablets are contraindicated in: - pregnant women. leflunomide tablets  may cause fetal harm. if a woman becomes pregnant while taking this drug, stop leflunomide tablets, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1 and 5.3) and use in specific populations (8.1)]. - patients with severe hepatic impairment [see warnings and precautions (5.2)]. - patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. known reactions include anaphylaxis [see adverse reactions (6.1)]. - patients being treated with teriflunomide [see drug interactions (7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy. health care providers and patients are encouraged to report pregnancies by calli

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; maize starch; magnesium stearate; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; colloidal anhydrous silica; maize starch; microcrystalline cellulose; magnesium stearate; crospovidone; lactose monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; povidone; magnesium stearate; crospovidone; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - leflunomide, quantity: 20 mg - tablet, uncoated - excipient ingredients: crospovidone; magnesium stearate; colloidal anhydrous silica; lactose - leflunomide apotex is indicated for the treatment of: active rheumatoid arthritis; active psoriatic arthritis. genrx leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of genrx leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).